Chemours Swings to Profit in Q3, Operating Expenses Tumble

Ticker: CC · Form: 10-Q · Filed: 2025-11-06T00:00:00.000Z

Sentiment: mixed

Topics: Chemicals, Earnings, 10-Q, Profitability, Operating Expenses, Taxation, Cash Flow

Related Tickers: CC, DD, CTVA

TL;DR

**Chemours' Q3 profit rebound is a mirage; year-to-date losses and rising tax provisions signal deeper issues for this chemical giant.**

AI Summary

Chemours Co (CC) reported a significant turnaround in net income for the three months ended September 30, 2025, achieving a net income of $60 million, a substantial improvement from a net loss of $32 million in the same period of 2024. This positive shift occurred despite a slight decrease in net sales, which fell to $1,495 million from $1,508 million year-over-year. The company's gross profit declined to $233 million from $286 million, primarily due to an increase in cost of goods sold from $1,222 million to $1,262 million. However, a notable reduction in total other operating expenses, which dropped from $267 million to $139 million, largely driven by the absence of a $56 million goodwill impairment charge seen in 2024 and lower restructuring charges, contributed to the improved bottom line. For the nine months ended September 30, 2025, Chemours reported a net loss of $324 million, a significant decline from a net income of $81 million in the prior year, primarily due to a substantial increase in the provision for income taxes to $114 million from $25 million and higher selling, general, and administrative expenses of $669 million compared to $428 million. Cash provided by operating activities for the nine months ended September 30, 2025, was $127 million, a strong recovery from cash used of $771 million in the same period of 2024.

Why It Matters

Chemours' return to profitability in Q3 2025, despite a slight revenue dip, signals effective cost management and a potential stabilization in its core chemical markets. The absence of a goodwill impairment charge and reduced restructuring costs are positive indicators for investors, suggesting a cleaner balance sheet and potentially fewer one-off expenses going forward. However, the year-to-date net loss of $324 million, largely driven by increased tax provisions and SG&A, highlights ongoing challenges and competitive pressures in the chemical industry, particularly for its Titanium Technologies and Advanced Performance Materials segments. Employees might see this as a sign of operational efficiency, while customers could benefit from a more stable supplier. The broader market will watch if this Q3 performance is sustainable amidst fluctuating raw material costs and global demand for performance chemicals.

Risk Assessment

Risk Level: medium — While Chemours reported a Q3 2025 net income of $60 million, a significant improvement from a $32 million loss in Q3 2024, the nine-month period shows a substantial net loss of $324 million compared to a net income of $81 million in the prior year. This is largely driven by a sharp increase in the provision for income taxes to $114 million for the nine months ended September 30, 2025, from $25 million in the same period of 2024, indicating potential future tax liabilities or changes in tax strategy that could impact profitability.

Analyst Insight

Investors should exercise caution and look beyond the Q3 net income, focusing on the year-to-date net loss of $324 million and the significant increase in the provision for income taxes. A deeper dive into the drivers of the increased tax provision and sustained higher SG&A expenses is warranted before making investment decisions. Consider holding or reducing exposure until a clearer path to sustained profitability emerges.

Financial Highlights

revenue
$1,495M
net Income
$60M
eps
$0.40
gross Margin
15.6%
revenue Growth
-0.9%

Revenue Breakdown

SegmentRevenueGrowth
Total Net Sales$1,495M-0.9%

Key Numbers

Key Players & Entities

FAQ

What were Chemours Co's net sales for the third quarter of 2025?

Chemours Co reported net sales of $1,495 million for the three months ended September 30, 2025, a slight decrease from $1,508 million in the same period of 2024.

How did Chemours' net income change in Q3 2025 compared to Q3 2024?

Chemours reported a net income of $60 million for the three months ended September 30, 2025, a significant improvement from a net loss of $32 million in the third quarter of 2024.

What was the primary reason for the improvement in Chemours' Q3 2025 net income?

The primary reason for the improvement was a substantial reduction in total other operating expenses, which decreased to $139 million in Q3 2025 from $267 million in Q3 2024, largely due to the absence of a $56 million goodwill impairment charge.

What was Chemours' net loss for the nine months ended September 30, 2025?

For the nine months ended September 30, 2025, Chemours reported a net loss of $324 million, a significant decline from a net income of $81 million in the prior year.

How did the provision for income taxes impact Chemours' year-to-date results?

The provision for income taxes significantly impacted year-to-date results, increasing to $114 million for the nine months ended September 30, 2025, from $25 million in the same period of 2024.

What was Chemours' cash flow from operating activities for the first nine months of 2025?

Chemours generated $127 million in cash from operating activities for the nine months ended September 30, 2025, a strong recovery compared to cash used of $771 million in the same period of 2024.

What were the key segments for Chemours Co?

Chemours manages and reports its operating results through three principal reportable segments: Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials.

What is the outstanding common stock for Chemours Co as of October 30, 2025?

As of October 30, 2025, The Chemours Company had 149,891,952 shares of common stock, $0.01 par value, outstanding.

Did Chemours Co revise any previously issued financial statements?

Yes, Chemours Co revised previously issued consolidated financial statements for immaterial errors related to byproduct revenue sales, ore sales, and timing of cost of goods sold recognition, impacting periods beginning January 1, 2022.

What are the main products offered by Chemours Co?

Chemours' principal products include refrigerants, titanium dioxide (TiO2) pigment, and industrial fluoropolymer resins, serving markets like refrigeration, coatings, plastics, and semiconductors.

Risk Factors

Industry Context

The chemical industry is characterized by cyclicality, intense competition, and significant capital investment. Companies like Chemours operate in segments such as Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials, facing pressures from raw material costs, environmental regulations, and global economic conditions. Innovation and sustainability are increasingly critical for competitive advantage.

Regulatory Implications

Chemours faces substantial regulatory scrutiny, particularly concerning PFAS chemicals, which could lead to increased compliance costs, operational restrictions, and significant legal liabilities. Adherence to evolving environmental standards is paramount for continued operation and market access.

What Investors Should Do

  1. [object Object]
  2. [object Object]
  3. [object Object]
  4. [object Object]

Key Dates

Glossary

Goodwill impairment charge
A charge taken when the carrying value of goodwill on a company's balance sheet is deemed to be impaired, meaning its fair value is less than its book value. (The absence of a $56 million goodwill impairment charge in Q3 2025 compared to Q3 2024 significantly contributed to the improved net income for the quarter.)
Restructuring, asset-related, and other charges
Costs incurred by a company related to significant reorganizations, asset disposals, or other unusual events. (Lower restructuring charges in Q3 2025 compared to Q3 2024 also aided the profitability improvement for the quarter.)
Provision for income taxes
The amount of tax expense that a company expects to pay on its taxable income for a given period. (A substantial increase in the provision for income taxes to $114 million in the nine months of 2025 from $25 million in the prior year negatively impacted year-to-date profitability.)
Selling, general, and administrative expense (SG&A)
Costs incurred by a company in the normal course of business, not directly related to the production of goods or services. (Higher SG&A expenses in the nine months of 2025 ($669 million) compared to 2024 ($428 million) contributed to the year-to-date net loss.)
Cash provided by operating activities
The net amount of cash generated from a company's normal business operations. (The strong recovery in cash from operations to $127 million for the nine months of 2025 from a significant outflow in 2024 indicates improved operational cash generation.)
Other comprehensive income (loss)
Unrealized gains or losses that are not included in net income but are reported in a separate section of the income statement. (Includes items like foreign currency translation adjustments and unrealized gains/losses on hedging activities, which can impact total equity but not immediate net income.)

Year-Over-Year Comparison

Compared to the prior year, Chemours has experienced a slight revenue decline in Q3 2025 (-0.9%) but a significant turnaround in net income for the quarter ($60M vs -$32M loss), largely due to a substantial reduction in other operating expenses, notably the absence of a goodwill impairment charge. However, the year-to-date performance shows a marked deterioration, with a net loss of $324M in 2025 compared to a net income of $81M in 2024, driven by higher income tax provisions and SG&A expenses. A key positive development is the strong recovery in cash from operating activities for the nine months, moving from a significant outflow to a positive inflow.

Filing Stats: 4,706 words · 19 min read · ~16 pages · Grade level 20 · Accepted 2025-11-06 16:34:47

Key Financial Figures

Filing Documents

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 69 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 96 Item 4.

Controls and Procedures

Controls and Procedures 97 Part II Other Information Item 1.

Legal Proceedings

Legal Proceedings 98 Item 1A.

Risk Factors

Risk Factors 98 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 101 Item 3. Defaults Upon Senior Securities 101 Item 4. Mine Safety Disclosures 101 Item 5. Other Information 101 Item 6. Exhibits 102 Signature 103 1

FINANCI AL INFORMATION

PART I. FINANCI AL INFORMATION

INTERIM CONSOLIDATED FINANCIAL STATEMENTS

Item 1. INTERIM CONSOLIDATED FINANCIAL STATEMENTS The Chemours Company Interim Consolidated Statemen ts of Operations (Unaudited) (Dollars in millions, except per share amounts) Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Net sales $ 1,495 $ 1,508 $ 4,478 $ 4,423 Cost of goods sold 1,262 1,222 3,732 3,546 Gross profit 233 286 746 877 Selling, general, and administrative expense 109 137 669 428 Research and development expense 26 29 81 83 Restructuring, asset-related, and other charges 4 45 55 52 Goodwill impairment charge — 56 — 56 Total other operating expenses 139 267 805 619 Equity in earnings of affiliates 9 11 27 34 Interest expense, net ( 68 ) ( 68 ) ( 201 ) ( 196 ) Other income, net 16 6 23 10 Income (loss) before income taxes 51 ( 32 ) ( 210 ) 106 (Benefit from) provision for income taxes ( 9 ) — 114 25 Net income (loss) 60 ( 32 ) ( 324 ) 81 Less: Net income attributable to non-controlling interests — — 1 — Net income (loss) attributable to Chemours $ 60 $ ( 32 ) $ ( 325 ) $ 81 Per share data Basic earnings (loss) per share of common stock $ 0.40 $ ( 0.22 ) $ ( 2.16 ) $ 0.54 Diluted earnings (loss) per share of common stock $ 0.40 $ ( 0.22 ) $ ( 2.16 ) $ 0.54 See accompanying notes to the interim consolidated financial statements. 2 The Chemours Company Interim Consolidated Statements of Comprehensive Income (Unaudited) (Dollars in millions) Three Months Ended September 30, 2025 2024 Pre-tax Tax After-tax Pre-tax Tax After-tax Net income (loss) $ 60 $ ( 32 ) Other comprehensive income (loss): Hedging activities: Unrealized gain (loss) on net investment hedge $ 7 $ ( 2 ) 5 $ ( 38 ) $ 9 ( 29

View on Read The Filing